ResearcherUniversity of Alabama at BirminghamActive in the last 2 years

Sumit Agarwal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4051-7146; OpenAlex author ID A5063558302. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.neo.2023.100951 ↗
PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Co-author DOI 10.1016/j.tranon.2020.100776 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Upender Manne Manne · 2 shared papers, 2020–2024 · strength 0.30
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Sooryanarayana Varambally · 2 shared papers, 2020–2024 · strength 0.30
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Farrukh Afaq · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Moh'd M. Khushman · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Priyabrata Mukherjee · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Subhash C. Chauhan · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Donald J Buchsbaum · 1 shared paper, 2020 · strength 0.10
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Isam‐Eldin A. Eltoum · 1 shared paper, 2020 · strength 0.10
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.